The ophthalmic rod--a new drug-delivery system II

Area of Science:

• Ophthalmology
• Drug Delivery Systems
• Materials Science

Background:

• Traditional eyedrops face challenges with preservation, sterility, and cross-infection risks.
• A new ophthalmic drug-delivery system, the ophthalmic rod (OR), utilizes a nontoxic plastic rod with the active substance as a thin film.
• The OR is designed as a single-dose sterile applicator, potentially overcoming common issues with eyedrops.

Purpose of the Study:

• To evaluate the efficacy and safety of the ophthalmic rod (OR) as a novel drug delivery system for ophthalmic medications.
• To assess the performance of clonidine ORs in managing ocular pressure in glaucoma patients.
• To determine the suitability of fluorescein ORs for tonometry and safety checks.

Main Methods:

• An open, uncontrolled study involving 15 glaucoma patients over 12 days.
• Clonidine ORs (20 micrograms/rod) were administered thrice daily to assess ocular pressure control.
• Fluorescein ORs (30 micrograms/rod) were used for tonometry and to evaluate safety, with quantitative analysis of remaining clonidine film.

Main Results:

• A dosage of 20 micrograms clonidine OR, applied three times daily, was sufficient to maintain ocular pressure control in glaucoma patients.
• Fluorescein ORs demonstrated satisfactory performance for corneal visualization during tonometry.
• No clinically apparent side effects were observed throughout the 12-day study period.

Conclusions:

• The ophthalmic rod (OR) presents a viable, sterile, and single-dose alternative to traditional eyedrops for ophthalmic drug delivery.
• The OR system effectively eliminates preservation and sterility concerns associated with eyedrops, while also mitigating cross-infection risks.
• Patients reported satisfaction with the OR method, highlighting its potential as a practical alternative for managing ocular conditions like glaucoma.